Anti-flt-1 antibodies in treating bronchopulmonary dysplasia

ABSTRACT

The present invention provides, among other things, methods and compositions for treating chronic lung disorders, in particular, bronchopulmonary dysplasia (BPD). In some embodiments, a method according to the present invention includes administering to an individual who is suffering from or susceptible to BPD an effective amount of an anti-Flt-1 antibody, or antigen binding fragment thereof, such that at least one symptom or feature of BPD is reduced in intensity, severity, or frequency, or has delayed onset.

RELATED APPLICATIONS

This application is a continuation of Ser. No. 15/564,969 filed Feb. 7,2018, which is a 35 U.S.C. § 371 National Stage Application ofInternational Application No. PCT/US2016/26420, filed Apr. 7, 2016,which claims priority to U.S. Provisional Application Ser. No.62/144,241, filed Apr. 7, 2015, the disclosure of which is herebyincorporated by reference.

INCORPORATION-BY-REFERENCE

The content of the text file named “SHR-1188US2_ST25.txt,” which wascreated on May 5, 2020 and is 1.78 KB in size, is hereby incorporated byreference in its entirety.

BACKGROUND

Bronchopulmonary dysplasia (BPD) is a severe, chronic lung disease thatprimarily affects premature infants. Premature infants can develop BPDafter their lungs have been damaged from the use of supplemental oxygenand mechanical breathing aids. Infants with BPD have inflammation andscarring in the lungs and in severe cases, are at high risk forprolonged need for ventilator or oxygen support, pulmonary hypertension,recurrent respiratory infections, abnormal lung function, exerciseintolerance, late neuro-developmental conditions, and even death.

Many infants with BPD recover and improve with time, however, thesechildren are at increased risk of developing further complications,including asthma and viral pneumonia. And while most infants survive,some infants with very severe BPD will still die from the disease evenafter months of care.

SUMMARY OF THE INVENTION

The present invention provides, among other things, improved methods andcompositions for treating chronic lung disorders, in particular,bronchopulmonary dysplasia (BPD), based on anti-Flt-1 antibody therapy.As described in the Examples below, the invention is, in part, based onthe discovery that anti-Flt-1 antibodies, or antigen binding fragmentsthereof, can inhibit VEGF and other ligands from binding to the Flt-1receptor, thereby increasing the amount VEGF and/or other ligandsavailable to bind to VEGF receptors. This increased binding can induce apro-angiogenic effect that increases capillary density and facilitatesreduction of fibrosis and inflammation, and mitigation of symptoms andfeatures associated with BPD. Indeed, as shown in the Examples, thepresent inventors have demonstrated that administration of an anti-Flt-1antibody improves measures of lung pathology in BPD animal models.Therefore, the present invention provides safe and effectiveantibody-based therapeutics for the treatment of BPD.

In one aspect, the present invention provides methods of treatingbronchopulmonary dysplasia (BPD) comprising administering to anindividual in need of treatment an effective amount of an anti-Flt-1antibody or antigen binding fragment thereof.

In some embodiments, an individual is an infant who is suffering from orsusceptible to BPD. In some embodiments, an individual is pregnant witha fetus who is suffering from or susceptible to BPD.

In some embodiments, an anti-Flt-1 antibody or antigen binding fragmentthereof is characterized with an ability to bind human Flt-1 at anaffinity greater than 10⁻⁹M, greater than 10⁻¹⁰M, or greater than 10⁻¹²Min a surface plasmon resonance binding assay.

In some embodiments, an anti-Flt-1 antibody or antigen binding fragmentthereof is characterized with an IC₅₀ below 100 pM, below 10 pM, orbelow 1 pM in a competition assay with human Flt-1.

In some embodiments, a competition assay is inhibition of binding ofVEGF to human Flt-1. In some embodiments, a competition assay isinhibition of binding of PLGF to human Flt-1.

In some embodiments, an anti-Flt-1 antibody or antigen binding fragmentthereof does not bind to VEGFR2 and/or VEGFR3.

In some embodiments, an anti-Flt-1 antibody or antigen binding fragmentthereof does not bind to a mouse or monkey Flt-1.

In some embodiments, an anti-Flt-1 antibody or antigen binding fragmentthereof binds to a mouse and/or monkey Flt-1.

In some embodiments, an anti-Flt-1 antibody or antigen binding fragmentthereof is selected from the group consisting of IgG, F(ab′)₂, F(ab)₂,Fab′, Fab, ScFvs, diabodies, triabodies and tetrabodies. In someembodiments, an anti-Flt-1 antibody or antigen binding fragment thereofis IgG. In some embodiments, an anti-Flt-1 antibody or antigen bindingfragment thereof is IgG1.

In some embodiments, an anti-Flt-1 antibody or antigen binding fragmentthereof is a monoclonal antibody. In some embodiments, a monoclonalantibody is a humanized monoclonal antibody. In some embodiments, ahumanized monoclonal antibody contains a human Fc region. In someembodiments, a Fc region contains one or more mutations that enhance thebinding affinity between the Fc region and the FcRn receptor such thatthe in vivo half-life of the antibody is prolonged. In some embodiments,a Fc region contains one or more mutations at one or more positionscorresponding to Thr 250, Met 252, Ser 254, Thr 256, Thr 307, Glu 380,Met 428, His 433, and/or Asn 434 of human IgG1.

In some embodiments, an anti-Flt-1 antibody or antigen binding fragmentthereof is administered parenterally. In some embodiments, parenteraladministration is selected from intravenous, intradermal, intrathecal,inhalation, transdermal (topical), intraocular, intramuscular,subcutaneous, pulmonary delivery, and/or transmucosal administration. Insome embodiments, parenteral administration is intravenousadministration.

In some embodiments, an anti-Flt-1 antibody or antigen binding fragmentthereof is administered orally.

In some embodiments, an anti-Flt-1 antibody or antigen binding fragmentthereof is administered bimonthly, monthly, triweekly, biweekly, weekly,daily, or at variable intervals.

In some embodiments, an anti-Flt-1 antibody or antigen binding fragmentthereof is delivered to one or more target tissues selected from lungsand heart. In some embodiments, an anti-Flt-1 antibody or antigenbinding fragment thereof is delivered to the lungs. In some embodiments,an anti-Flt-1 antibody, or an antigen binding fragment thereof, isdelivered to the heart.

In some embodiments, administration of an anti-Flt-1 antibody or antigenbinding fragment thereof results in growth of healthy lung tissue,decreased lung inflammation, increased alveologenesis, increasedangiogenesis, improved structure of pulmonary vascular bed, reduced lungscarring, improved lung growth, reduced respiratory insufficiency,improved exercise tolerance, reduced adverse neurological outcome,and/or improved pulmonary function relative to a control.

In some embodiments, the present invention provides a method furthercomprising co-administering at least one additional agent or therapyselected from a surfactant, oxygen therapy, ventilator therapy, asteroid, vitamin A, inhaled nitric oxide, high calorie nutritionalformulation, a diuretic, and/or a bronchodilator.

As used in this application, the terms “about” and “approximately” areused as equivalents. Any numerals used in this application with orwithout about/approximately are meant to cover any normal fluctuationsappreciated by one of ordinary skill in the relevant art.

Other features, objects, and advantages of the present invention areapparent in the detailed description that follows. It should beunderstood, however, that the detailed description, while indicatingembodiments of the present invention, is given by way of illustrationonly, not limitation. Various changes and modifications within the scopeof the invention will become apparent to those skilled in the art fromthe detailed description.

BRIEF DESCRIPTION OF THE DRAWINGS

FIG. 1 shows exemplary results illustrating the anti-soluble human Flt-1antiserum titer of mice immunized with soluble human Flt-1 antigen.

FIG. 2 shows exemplary results illustrating competitive binding ofmonoclonal antibodies with human soluble Flt-1 in an ELISA.

FIG. 3 shows exemplary monoclonal antibody binding to soluble humanFlt-1.

FIG. 4 shows exemplary results illustrating monoclonal antibody bindingto soluble human Flt-1 via surface plasmon resonance (BIACORE) assay.

FIG. 5 shows exemplary results illustrating cross-reactivity ofmonoclonal antibody binding with cyno (monkey) Flt-1.

FIG. 6 shows exemplary results illustrating competitive binding ofmonoclonal antibodies with human soluble Flt-1 in an ELISA. VEGF:sFlt-1IC₅₀ determination of monoclonal antibody 01A04 (sub-clone 02B10-02G07)versus a commercial benchmark is depicted.

FIG. 7 shows exemplary results illustrating anti-Flt-1 monoclonalantibody inhibition of VEGF binding to sFlt-1 in a cell based assay.

FIG. 8 shows exemplary results illustrating pulmonary artery endothelialcell (PAEC) growth 3 days after treatment.

FIG. 9 shows exemplary results illustrating PAEC growth 3 days aftertreatment.

FIG. 10 shows exemplary results illustrating tube formation 24 hoursafter treatment.

FIG. 11 shows exemplary results illustrating tube formation 24 hoursafter treatment.

FIG. 12 shows exemplary results illustrating the effects of in uterodosing of Vitamin D in an endotoxin (ETX) induced model of BPD in rats.

FIG. 13 shows exemplary results illustrating the effects of in uterodosing of anti-Flt-1 monoclonal antibody in an endotoxin (ETX) inducedmodel of BPD in rats.

FIG. 14 shows exemplary results illustrating the effects of in uterodosing of anti-Flt-1 monoclonal antibody in a soluble Flt1 (sFLT)induced model of BPD on pulmonary vessel density in rats.

FIG. 15 shows exemplary results illustrating the effects of in uterodosing of anti-Flt-1 monoclonal antibody in a soluble Flt1 (sFLT)induced model of BPD on pulmonary vessel density in rats.

FIG. 16 shows exemplary results illustrating the effects of low and highdoses of anti-Flt-1 monoclonal antibody (a-sFLT) in a soluble Flt1(sFLT) induced model of BPD in rats.

FIG. 17 shows exemplary results illustrating the effects of low and highdoses of anti-Flt-1 monoclonal antibody (a-sFLT) in a soluble Flt1(sFLT) induced model of BPD in rats.

FIG. 18 shows exemplary results illustrating the effects of low and highdoses of anti-Flt-1 monoclonal antibody (a-sFLT) in a soluble Flt1(sFLT) induced model of BPD in rats.

FIG. 19 shows exemplary results illustrating the effects of 1 mg/kg and10 mg/kg postnatal doses of anti-Flt-1 monoclonal antibody (antisFLT) onbody weight in an endotoxin (ETX) induced model of BPD in rats.

FIG. 20 shows exemplary results illustrating the effects of 1 mg/kg and10 mg/kg postnatal doses of anti-Flt-1 monoclonal antibody (Mab) onradial alveolar count (RAC) in an endotoxin (ETX) induced model of BPDin rats.

FIG. 21 shows exemplary results illustrating the effects of 1 mg/kg and10 mg/kg postnatal doses of anti-Flt-1 monoclonal antibody (antisFLT) onright ventricular hypertrophy (RVH) in an endotoxin (ETX) induced modelof BPD in rats.

FIG. 22 shows exemplary results illustrating the effects of 1 mg/kg and10 mg/kg postnatal doses of anti-Flt-1 monoclonal antibody (anti-sFLT)on lung structure in an endotoxin (ETX) induced model of BPD in rats.

DEFINITIONS

In order for the present invention to be more readily understood,certain terms are first defined below. Additional definitions for thefollowing terms and other terms are set forth throughout thespecification.

Animal: As used herein, the term “animal” refers to any member of theanimal kingdom. In some embodiments, “animal” refers to humans, at anystage of development. In some embodiments, “animal” refers to non-humananimals, at any stage of development. In certain embodiments, thenon-human animal is a mammal (e.g., a rodent, a mouse, a rat, a rabbit,a monkey, a dog, a cat, a sheep, cattle, a primate, and/or a pig). Insome embodiments, animals include, but are not limited to, mammals,birds, reptiles, amphibians, fish, insects, and/or worms. In someembodiments, an animal may be a transgenic animal,genetically-engineered animal, and/or a clone.

Antibody: As used herein, the term “antibody” refers to anyimmunoglobulin, whether natural or wholly or partially syntheticallyproduced. All derivatives thereof which maintain specific bindingability are also included in the term. The term also covers any proteinhaving a binding domain which is homologous or largely homologous to animmunoglobulin-binding domain. Such proteins may be derived from naturalsources, or partly or wholly synthetically produced. An antibody may bemonoclonal or polyclonal. An antibody may be a member of anyimmunoglobulin class, including any of the human classes: IgG, IgM, IgA,IgD, and IgE. In certain embodiments, an antibody may be a member of theIgG immunoglobulin class. As used herein, the terms “antibody fragment”or “characteristic portion of an antibody” are used interchangeably andrefer to any derivative of an antibody that is less than full-length. Ingeneral, an antibody fragment retains at least a significant portion ofthe full-length antibody's specific binding ability. Examples ofantibody fragments include, but are not limited to, Fab, Fab′, F(ab′)₂,scFv, Fv, dsFv diabody, and Fd fragments. An antibody fragment may beproduced by any means. For example, an antibody fragment may beenzymatically or chemically produced by fragmentation of an intactantibody and/or it may be recombinantly produced from a gene encodingthe partial antibody sequence. Alternatively or additionally, anantibody fragment may be wholly or partially synthetically produced. Anantibody fragment may optionally comprise a single chain antibodyfragment. Alternatively or additionally, an antibody fragment maycomprise multiple chains that are linked together, for example, bydisulfide linkages. An antibody fragment may optionally comprise amultimolecular complex. A functional antibody fragment typicallycomprises at least about 50 amino acids and more typically comprises atleast about 200 amino acids. In some embodiments, an antibody may be ahuman antibody. In some embodiments, an antibody may be a humanizedantibody.

Antigen binding fragment: As used herein, the term “antigen bindingfragment” refers to a portion of an immunoglobulin molecule thatcontacts and binds to an antigen (i.e., Flt-1).

Approximately or about: As used herein, the term “approximately” or“about,” as applied to one or more values of interest, refers to a valuethat is similar to a stated reference value. In certain embodiments, theterm “approximately” or “about” refers to a range of values that fallwithin 25%, 20%, 19%, 18%, 17%, 16%, 15%, 14%, 13%, 12%, 11%, 10%, 9%,8%, 7%, 6%, 5%, 4%, 3%, 2%, 1%, or less in either direction (greaterthan or less than) of the stated reference value unless otherwise statedor otherwise evident from the context (except where such number wouldexceed 100% of a possible value).

Biologically active: As used herein, the phrase “biologically active”refers to a characteristic of any agent that has activity in abiological system, and particularly in an organism. For instance, anagent that, when administered to an organism, has a biological effect onthat organism, is considered to be biologically active. In particularembodiments, where a peptide is biologically active, a portion of thatpeptide that shares at least one biological activity of the peptide istypically referred to as a “biologically active” portion. In certainembodiments, a peptide has no intrinsic biological activity but thatinhibits the binding of one or more VEGF ligands, is considered to bebiologically active.

Carrier or diluent: As used herein, the terms “carrier” and “diluent”refer to a pharmaceutically acceptable (e.g., safe and non-toxic foradministration to a human) carrier or diluting substance useful for thepreparation of a pharmaceutical formulation. Exemplary diluents includesterile water, bacteriostatic water for injection (BWFI), a pH bufferedsolution (e.g. phosphate-buffered saline), sterile saline solution,Ringer's solution or dextrose solution.

Dosage form: As used herein, the terms “dosage form” and “unit dosageform” refer to a physically discrete unit of a therapeutic protein(e.g., antibody) for the patient to be treated. Each unit contains apredetermined quantity of active material calculated to produce thedesired therapeutic effect. It will be understood, however, that thetotal dosage of the composition will be decided by the attendingphysician within the scope of sound medical judgment.

Functional equivalent or derivative: As used herein, the term“functional equivalent” or “functional derivative” denotes, in thecontext of a functional derivative of an amino acid sequence, a moleculethat retains a biological activity (either function or structural) thatis substantially similar to that of the original sequence. A functionalderivative or equivalent may be a natural derivative or is preparedsynthetically. Exemplary functional derivatives include amino acidsequences having substitutions, deletions, or additions of one or moreamino acids, provided that the biological activity of the protein isconserved. The substituting amino acid desirably has chemico-physicalproperties that are similar to that of the substituted amino acid.Desirable similar chemico-physical properties include similarities incharge, bulkiness, hydrophobicity, hydrophilicity, and the like.

Fusion protein: As used herein, the term “fusion protein” or “chimericprotein” refers to a protein created through the joining of two or moreoriginally separate proteins, or portions thereof. In some embodiments,a linker or spacer will be present between each protein.

Half-life: As used herein, the term “half-life” is the time required fora quantity such as protein concentration or activity to fall to half ofits value as measured at the beginning of a time period.

Hypertrophy: As used herein the term “hypertrophy” refers to theincrease in volume of an organ or tissue due to the enlargement of itscomponent cells.

Improve, increase, or reduce: As used herein, the terms “improve,”“increase” or “reduce,” or grammatical equivalents, indicate values thatare relative to a baseline measurement, such as a measurement in thesame individual prior to initiation of the treatment described herein,or a measurement in a control subject (or multiple control subjects) inthe absence of the treatment described herein. A “control subject” is asubject afflicted with the same form of disease as the subject beingtreated, who is about the same age as the subject being treated.

In vitro: As used herein, the term “in vitro” refers to events thatoccur in an artificial environment, e.g., in a test tube or reactionvessel, in cell culture, etc., rather than within a multi-cellularorganism.

In vivo: As used herein, the term “in vivo” refers to events that occurwithin a multi-cellular organism, such as a human and a non-humananimal. In the context of cell-based systems, the term may be used torefer to events that occur within a living cell (as opposed to, forexample, in vitro systems).

Linker: As used herein, the term “linker” refers to, in a fusionprotein, an amino acid sequence other than that appearing at aparticular position in the natural protein and is generally designed tobe flexible or to interpose a structure, such as an α-helix, between twoprotein moieties. A linker is also referred to as a spacer. A linker ora spacer typically does not have biological function on its own.

Pharmaceutically acceptable: As used herein, the term “pharmaceuticallyacceptable” refers to substances that, within the scope of sound medicaljudgment, are suitable for use in contact with the tissues of humanbeings and animals without excessive toxicity, irritation, allergicresponse, or other problem or complication, commensurate with areasonable benefit/risk ratio.

Polypeptide: As used herein, the term “polypeptide” refers to asequential chain of amino acids linked together via peptide bonds. Theterm is used to refer to an amino acid chain of any length, but one ofordinary skill in the art will understand that the term is not limitedto lengthy chains and can refer to a minimal chain comprising two aminoacids linked together via a peptide bond. As is known to those skilledin the art, polypeptides may be processed and/or modified.

Prevent: As used herein, the term “prevent” or “prevention”, when usedin connection with the occurrence of a disease, disorder, and/orcondition, refers to reducing the risk of developing the disease,disorder and/or condition. See the definition of “risk.”

Protein: As used herein, the term “protein” refers to one or morepolypeptides that function as a discrete unit. If a single polypeptideis the discrete functioning unit and does not require permanent ortemporary physical association with other polypeptides in order to formthe discrete functioning unit, the terms “polypeptide” and “protein” maybe used interchangeably. If the discrete functional unit is comprised ofmore than one polypeptide that physically associate with one another,the term “protein” refers to the multiple polypeptides that arephysically coupled and function together as the discrete unit.

Risk: As will be understood from context, a “risk” of a disease,disorder, and/or condition comprises a likelihood that a particularindividual will develop a disease, disorder, and/or condition (e.g.,BPD). In some embodiments, risk is expressed as a percentage. In someembodiments, risk is from 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 20, 30, 40,50, 60, 70, 80, 90 up to 100%. In some embodiments risk is expressed asa risk relative to a risk associated with a reference sample or group ofreference samples. In some embodiments, a reference sample or group ofreference samples have a known risk of a disease, disorder, conditionand/or event (e.g., BPD). In some embodiments a reference sample orgroup of reference samples are from individuals comparable to aparticular individual. In some embodiments, relative risk is 0, 1, 2, 3,4, 5, 6, 7, 8, 9, 10, or more.

Subject: As used herein, the term “subject” refers to a human or anynon-human animal (e.g., mouse, rat, rabbit, dog, cat, cattle, swine,sheep, horse or primate). A human includes pre- and post-natal forms. Inmany embodiments, a subject is a human being. A subject can be apatient, which refers to a human presenting to a medical provider fordiagnosis or treatment of a disease. The term “subject” is used hereininterchangeably with “individual” or “patient.” A subject can beafflicted with or susceptible to a disease or disorder but may or maynot display symptoms of the disease or disorder.

Substantially: As used herein, the term “substantially” refers to thequalitative condition of exhibiting total or near-total extent or degreeof a characteristic or property of interest. One of ordinary skill inthe biological arts will understand that biological and chemicalphenomena rarely, if ever, go to completion and/or proceed tocompleteness or achieve or avoid an absolute result. The term“substantially” is therefore used herein to capture the potential lackof completeness inherent in many biological and chemical phenomena.

Substantial homology: As used herein, the phrase “substantial homologyrefers to a comparison between amino acid or nucleic acid sequences. Aswill be appreciated by those of ordinary skill in the art, two sequencesare generally considered to be “substantially homologous” if theycontain homologous residues in corresponding positions. Homologousresidues may be identical residues. Alternatively, homologous residuesmay be non-identical residues will appropriately similar structuraland/or functional characteristics. For example, as is well known bythose of ordinary skill in the art, certain amino acids are typicallyclassified as “hydrophobic” or “hydrophilic” amino acids, and/or ashaving “polar” or “non-polar” side chains. Substitution of one aminoacid for another of the same type may often be considered a “homologous”substitution.

As is well known in this art, amino acid or nucleic acid sequences maybe compared using any of a variety of algorithms, including thoseavailable in commercial computer programs such as BLASTN for nucleotidesequences and BLASTP, gapped BLAST, and PSI-BLAST for amino acidsequences. Exemplary such programs are described in Altschul, et al.,basic local alignment search tool, J. Mol. Biol., 215(3): 403-410, 1990;Altschul, et al., Methods in Enzymology; Altschul, et al., “Gapped BLASTand PSI-BLAST: a new generation of protein database search programs”,Nucleic Acids Res. 25:3389-3402, 1997; Baxevanis, et al.,Bioinformatics: A Practical Guide to the Analysis of Genes and Proteins,Wiley, 1998; and Misener, et al., (eds.), Bioinformatics Methods andProtocols (Methods in Molecular Biology, Vol. 132), Humana Press, 1999.In addition to identifying homologous sequences, the programs mentionedabove typically provide an indication of the degree of homology. In someembodiments, two sequences are considered to be substantially homologousif at least 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 91%, 92%, 93%,94%, 95%, 96%, 97%, 98%, 99% or more of their corresponding residues arehomologous over a relevant stretch of residues. In some embodiments, therelevant stretch is a complete sequence. In some embodiments, therelevant stretch is at least 10, 15, 20, 25, 30, 35, 40, 45, 50, 55, 60,65, 70, 75, 80, 85, 90, 95, 100, 125, 150, 175, 200, 225, 250, 275, 300,325, 350, 375, 400, 425, 450, 475, 500 or more residues.

Substantial identity: As used herein, the phrase “substantial identity”is used to refer to a comparison between amino acid or nucleic acidsequences. As will be appreciated by those of ordinary skill in the art,two sequences are generally considered to be “substantially identical”if they contain identical residues in corresponding positions. As iswell known in this art, amino acid or nucleic acid sequences may becompared using any of a variety of algorithms, including those availablein commercial computer programs such as BLASTN for nucleotide sequencesand BLASTP, gapped BLAST, and PSI-BLAST for amino acid sequences.Exemplary such programs are described in Altschul, et al., Basic localalignment search tool, J. Mol. Biol., 215(3): 403-410, 1990; Altschul,et al., Methods in Enzymology; Altschul et al., Nucleic Acids Res.25:3389-3402, 1997; Baxevanis et al., Bioinformatics: A Practical Guideto the Analysis of Genes and Proteins, Wiley, 1998; and Misener, et al.,(eds.), Bioinformatics Methods and Protocols (Methods in MolecularBiology, Vol. 132), Humana Press, 1999. In addition to identifyingidentical sequences, the programs mentioned above typically provide anindication of the degree of identity. In some embodiments, two sequencesare considered to be substantially identical if at least 50%, 55%, 60%,65%, 70%, 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%,99% or more of their corresponding residues are identical over arelevant stretch of residues. In some embodiments, the relevant stretchis a complete sequence. In some embodiments, the relevant stretch is atleast 10, 15, 20, 25, 30, 35, 40, 45, 50, 55, 60, 65, 70, 75, 80, 85,90, 95, 100, 125, 150, 175, 200, 225, 250, 275, 300, 325, 350, 375, 400,425, 450, 475, 500 or more residues.

Suffering from: An individual who is “suffering from” a disease,disorder, and/or condition has been diagnosed with or displays one ormore symptoms of the disease, disorder, and/or condition.

Susceptible to: An individual who is “susceptible to” a disease,disorder, and/or condition has not been diagnosed with the disease,disorder, and/or condition. In some embodiments, an individual who issusceptible to a disease, disorder, and/or condition may not exhibitsymptoms of the disease, disorder, and/or condition. In someembodiments, an individual who is susceptible to a disease, disorder,condition, or event (for example, BPD) may be characterized by one ormore of the following: (1) a genetic mutation associated withdevelopment of the disease, disorder, and/or condition; (2) a geneticpolymorphism associated with development of the disease, disorder,and/or condition; (3) increased and/or decreased expression and/oractivity of a protein associated with the disease, disorder, and/orcondition; (4) habits and/or lifestyles associated with development ofthe disease, disorder, condition, and/or event (5) having undergone,planning to undergo, or requiring a transplant. In some embodiments, anindividual who is susceptible to a disease, disorder, and/or conditionwill develop the disease, disorder, and/or condition. In someembodiments, an individual who is susceptible to a disease, disorder,and/or condition will not develop the disease, disorder, and/orcondition.

Target tissues: As used herein, the term “target tissues” refers to anytissue that is affected by a disease to be treated such as BPD. In someembodiments, target tissues include those tissues that displaydisease-associated pathology, symptom, or feature, including but notlimited to lung inflammation, lung scarring, impaired lung growth, earlylung injury, prolonged respiratory insufficiency, lung infections,exercise intolerance, and adverse neurological outcome.

Therapeutically effective amount: As used herein, the term“therapeutically effective amount” of a therapeutic agent means anamount that is sufficient, when administered to a subject suffering fromor susceptible to a disease, disorder, and/or condition, to treat,diagnose, prevent, and/or delay the onset of the symptom(s) of thedisease, disorder, and/or condition. It will be appreciated by those ofordinary skill in the art that a therapeutically effective amount istypically administered via a dosing regimen comprising at least one unitdose.

Treating: As used herein, the term “treat,” “treatment,” or “treating”refers to any method used to partially or completely alleviate,ameliorate, relieve, inhibit, prevent, delay onset of, reduce severityof and/or reduce incidence of one or more symptoms or features of aparticular disease, disorder, and/or condition. Treatment may beadministered to a subject who does not exhibit signs of a disease and/orexhibits only early signs of the disease for the purpose of decreasingthe risk of developing pathology associated with the disease.

DETAILED DESCRIPTION OF CERTAIN EMBODIMENTS

The present invention provides, among other things, methods andcompositions for treating chronic lung disorders, in particular,bronchopulmonary dysplasia (BPD), based on the use of anti-Flt-1antibodies, or antigen binding fragments thereof, as therapeutics fortreating BPD. In some embodiments, the present invention providesmethods of treating BPD including administering to an individual who issuffering from or susceptible to BPD an effective amount of an Flt-1antibody or antigen binding fragment thereof such that at least onesymptom or feature of BPD is reduced in intensity, severity, orfrequency, or has delayed onset.

Various aspects of the invention are described in detail in thefollowing sections. The use of sections is not meant to limit theinvention. Each section can apply to any aspect of the invention. Inthis application, the use of “or” means “and/or” unless statedotherwise.

Bronchopulmonary Dysplasia (BPD)

With the introduction of surfactant therapy, maternal steroids, newventilator strategies, aggressive management of the patent ductusarteriosus, improved nutrition, and other treatments, the clinicalcourse and outcomes of premature newborns with RDS have dramaticallychanged over the past 30 years. It has recently been demonstrated thatabout two thirds of infants who develop BPD have only mild respiratorydistress at birth. This suggests that developmental timing of lunginjury is a critical factor in the etiology of BPD.

In parallel with this changing epidemiologic and clinical pattern, keyfeatures of lung histology in BPD have also changed. There is nowgrowing recognition that infants with persistent lung disease afterpremature birth have a different clinical course and pathology than wastraditionally observed in infants dying with BPD during thispresurfactant era. The classic progressive stages that firstcharacterized BPD are often absent owing to changes in clinicalmanagement, and BPD has clearly changed from being predominantly definedby the severity of acute lung injury to its current characterization,which is primarily defined by a disruption of distal lung growth. Thus,the so-called new BPD of the postsurfactant period represents inhibitionof lung development with altered lung structure, growth, and function ofthe distal airspaces and vasculature. Physiologically, this suggests amarked reduction in alveolo-capillary surface area, potentiallycontributing to impaired gas exchange with increased risk for exerciseintolerance, pulmonary hypertension, and poor tolerance of acuterespiratory infections.

Pathogenesis of BPD

BPD represents the response of the lung to injury during a criticalperiod of lung growth, that is, during the canalicular period (17 to 26weeks in the human), a time during which airspace septation and vasculardevelopment increase dramatically. In some embodiments, factors thatincrease the susceptibility of the premature newborn to the developmentof BPD, include surfactant deficiency, decreased antioxidant defenses,impaired epithelial ion and water transport function, and lungstructural immaturity. In some embodiments, lung injury after prematurebirth and the subsequent arrest of lung growth results from complexinteractions between multiple adverse stimuli, including inflammation,hyperoxia, mechanical ventilation, and infection, of the poorly defendeddeveloping lung. In some embodiments, prenatal exposure toproinflammatory cytokines, such as TNF-α, IL-6, IL-8, and others, due tomaternal chorioamnionitis, enhance lung maturation in utero, butincrease the risk for BPD.

Hyperoxia and oxidant stress are critical factors in the development ofBPD. In some embodiments, the transition of the premature newborn fromthe low-oxygen tension environment of the normal fetus to the relativehyperoxia of extrauterine life increases the risk for BPD with decreasedalveolarization and a dysmorphic vasculature. In some embodiments, thepremature change in the oxygen environment impedes normalepithelial-mesenchymal interactions and leads to alterations inendothelial cell survival, differentiation, and organization in themicrovasculature. In some embodiments, a premature infant is especiallysusceptible to reactive oxidant species (ROS)-induced damage owing tothe lack of adequate antioxidants after premature birth. In someembodiments, antioxidant enzymes [e.g., superoxide dismutase (SOD),catalase, and glutathione peroxidase] markedly increase during lategestation. In some additional embodiments, the ability to increasesynthesis of antioxidant enzymes in response to hyperoxia is decreasedin preterm animals, so premature birth may precede the normalup-regulation of antioxidants, which persists during early postnatallife. In some embodiments, endothelial and alveolar type II cells areextremely susceptible to hyperoxia and ROS-induced injury, leading toincreased edema, cellular dysfunction, and impaired cell survival andgrowth.

In some embodiments, even in the absence of overt signs of baro- orvolutrauma, treatment of premature neonates with mechanical ventilationinitiates and promotes lung injury with inflammation and permeabilityedema, and contributes to BPD. In some embodiments,ventilator-associated lung injury (VALI) results from stretching distalairway epithelium and capillary endothelium, which increasespermeability edema, inhibits surfactant function, and provokes a complexinflammatory cascade. In some embodiments, even brief periods ofpositive-pressure ventilation, such as during resuscitation in thedelivery room, can cause bronchiolar epithelial and endothelial damagein the lung, setting the stage for progressive lung inflammation andinjury.

Lung inflammation, whether induced prior to birth (fromchorioamnionitis) or during the early postnatal period (due to hyperoxiaor VALI) plays a prominent role in the development of BPD. In someembodiments, the risk for BPD is associated with sustained increases intracheal fluid neutrophil counts, activated macrophages, highconcentrations of lipid products, oxidant-inactivated α-1-antitrypsinactivity, and proinflammatory cytokines, including IL-6 and IL-8, anddecreased IL-10 levels. In some embodiments, release of early responsecytokines, such as TNF-α, IL-1β, IL-8, and TGF-β, by macrophages and thepresence of soluble adhesion molecules (i.e., selectins) may impactother cells to release chemoattractants that recruit neutrophils andamplify the inflammatory response. In some embodiments, elevatedconcentrations of proinflammatory cytokines in conjunction with reducedanti-inflammatory products (i.e., IL-10) appear in tracheal aspirateswithin a few hours of life in infants subsequently developing BPD. Insome embodiments, increased elastase and collagenase release fromactivated neutrophils may directly destroy the elastin and collagenframework of the lung, and markers of collagen and elastin degradationcan be recovered in the urine of infants with BPD. In some embodiments,infection from relatively low virulence organisms, such as airwaycolonization with Ureaplasma urealyticum, may augment the inflammatoryresponse, further increasing to the risk for BPD. In some embodiments,other factors, such as nutritional deficits and genetic factors, such asvitamin A and E deficiency or single nucleotide polymorphism variants ofthe surfactant proteins, respectively, are likely to increase risk forBPD in some premature newborns.

Pulmonary Circulation in BPD

In addition to adverse effects on the airway and distal airspace, acutelung injury also impairs growth, structure, and function of thedeveloping pulmonary circulation after premature birth. In someembodiments, endothelial cells are particularly susceptible to oxidantinjury through hyperoxia or inflammation. In some embodiments, the mediaof small pulmonary arteries undergoes striking changes, including smoothmuscle cell proliferation, precocious maturation of immature mesenchymalcells into mature smooth muscle cells, and incorporation offibroblasts/myofibroblasts into the vessel wall. In some embodiments,structural changes in the lung vasculature contribute to high pulmonaryvascular resistance (PVR) through narrowing of the vessel diameter anddecreased vascular compliance. In some embodiments, in addition to thesestructural changes, the pulmonary circulation is further characterizedby abnormal vasoreactivity, which also increases PVR. In someembodiments, decreased angiogenesis may limit vascular surface area,causing further elevations of PVR, especially in response to highcardiac output with exercise or stress.

Overall, early injury to the lung circulation leads to the rapiddevelopment of pulmonary hypertension, which contributes significantlyto the morbidity and mortality of severe BPD. In some embodiments, highmortality rates occur in infants with BPD and pulmonary hypertension whorequire prolonged ventilator support. In some embodiments, pulmonaryhypertension is a marker of more advanced BPD, and elevated PVR alsocauses poor right ventricular function, impaired cardiac output, limitedoxygen delivery, increased pulmonary edema and, perhaps, a higher riskfor sudden death. In some embodiments, physiologic abnormalities of thepulmonary circulation in BPD include elevated PVR and abnormalvasoreactivity, as evidenced by the marked vasoconstrictor response toacute hypoxia. In some embodiments, even mild hypoxia causes markedelevations in pulmonary artery pressure in infants with modest basallevels of pulmonary hypertension. In some embodiments, treatment levelsof oxygen saturations above 92-94% effectively lower pulmonary arterypressure. In some embodiments, strategies to lower pulmonary arterypressure or limit injury to the pulmonary vasculature may limit thesubsequent development of pulmonary hypertension in BPD.

Finally, pulmonary hypertension and right heart function remain majorclinical concerns in infants with BPD. In some embodiments, pulmonaryvascular disease in BPD also includes reduced pulmonary artery densityowing to impaired growth, which contributes to physiologic abnormalitiesof impaired gas exchange, as well as to the actual pathogenesis of BPD.In some embodiments, impaired angiogenesis impedes alveolarization andstrategies that preserve and enhance endothelial cell survival, growth,and function provide therapeutic approaches for the prevention of BPD.

Altered Signaling of Angiogenic Factors in BPD

Multiple growth factors and signaling systems play important roles innormal lung vascular growth. In some embodiments, premature delivery andchanges in oxygen tension, inflammatory cytokines, and other signalsalter normal growth factor expression and signaling and thus lung/lungvascular development. In some embodiments, the growth factor is VEGF.Impaired VEGF signaling has been associated with the pathogenesis of BPDin the clinical setting. In some embodiments, VEGF is found to be lowerin tracheal fluid samples from premature neonates who subsequentlydevelop BPD than those who do not develop chronic lung disease (185). Insome embodiments, hyperoxia down-regulates lung VEGF expression, andpharmacologic inhibition of VEGF signaling impairs lung vascular growthand inhibits alveolarization. The biologic basis for impaired VEGFsignaling leading to decreased vascular growth and impairedalveolarization is well established.

Vascular Growth and Alveolarization

As described above, close coordination of growth between airways andvessels is essential for normal lung development. In some embodiments,failure of pulmonary vascular growth during a critical period of lunggrowth (saccular or alveolar stages of development) decreases septationand ultimately contributes to the lung hypoplasia that characterizesBPD. In some embodiments, angiogenesis is involved in alveolarizationduring lung development and mechanisms that injure and inhibit lungvascular growth may impede alveolar growth after premature birth. Insome embodiments, inhibition of lung vascular growth during a criticalperiod of postnatal lung growth impairs alveolarization.

Flt-1 Receptor

Flt-1 receptor, also known as vascular endothelial growth factorreceptor 1, is a receptor that is encoded by the FLT1 gene. The vascularendothelial growth factor (VEGF) family of signal glycoproteins act aspotent promoters of angiogenesis during embryogenesis and postnatalgrowth. Specifically, the binding of the VEGF-A ligand with the VEGFreceptors has been shown to promote vascular permeability and alsotrigger endothelial cell migration, proliferation, and survival, and thenewly formed endothelial cells provide the basic structure of newvasculatures. The dominant VEGF signal molecule for angiogenesis,VEGF-A, mediates its signal through VEGF receptor-1 (VEGFR-1, also knownas Flt-1) and VEGF receptor-2 (VEGFR-2, also known as Flk-1). A solubleform of Flt-1 (sFlt-1) also exists, but lacks an intracellular signalingdomain and thus is believed to only serve in a regulatory capacity bysequestering VEGF-A or other ligands that bind to it. sFlt-1 and othermolecules containing Flt-1 binding sites that are not linked to anintracellular signal transduction pathway are referred to as “decoyreceptors”. Flt-1 and Flk-1 receptors contain an extracellularVEGF-A-binding domain and an intracellular tyrosine kinase domain, andboth show expression during the developmental stage and tissueregeneration in hemangioblasts and endothelial cell lineages. Flt-1 hasabout 10 times greater binding affinity for VEGF-A (Kd ˜2-10 pM)compared to Flk-1, but the weaker tyrosine kinase domain indicates thatangiogenic signal transduction following VEGF-A binding to Flt-1 iscomparably weaker than the Flk-1 signal. As such, homozygous Flt-1 geneknockout mice die in the embryonic stage from endothelial celloverproduction and blood vessel disorganization. Inversely, homozygousFlk-1 gene knockout mice die from defects in the development oforganized blood vessels due to lack of yolk-sac blood island formationduring embryogenesis. Both the Flt-1 and Flk-1 receptors are needed fornormal development, but selective augmentation in VEGF-A concentrationmay allow for greater binding to the Flk-1 receptor and induce apro-angiogenic effect that increases capillary density and facilitatesreduction of fibrosis and inflammation, and mitigation of symptoms andfeatures associated with BPD.

As used herein, the term “Flt-1 receptor” refers to both soluble andmembrane associated Flt-1 receptors, or functional fragments thereof.

Anti-Flt-1 Antibodies

As used herein, the term “anti-Flt-1 antibodies” refers to anyantibodies, or antigen binding fragments thereof, that bind to an Flt-1receptor (e.g., soluble or membrane associated Flt-1 receptor). In someembodiments, anti-Flt-1 antibodies are produced that bind with highaffinity to Flt-1 receptors. Without wishing to be bound by theory, itis believed that anti-Flt-1 antibody binding to Flt-1 receptors inhibitsone or more endogenous ligands from binding to Flt-1 and therebyallowing a greater amount of available ligand to associate with otherVEGF receptors, such as the Flk-1 receptor. Increased activation of theFlk-1 receptor could increases capillary density and facilitatesreduction of fibrosis and inflammation, and mitigation of symptoms andfeatures associated with BPD. In some embodiments, antibody binding toFlt-1 receptors increases the amount of VEGF available to bind to otherVEGF receptors. In some embodiments, antibody binding to Flt-1 receptorsincreases the amount of placental growth factor (PLGF) available to bindto other VEGF receptors.

In some embodiments, an anti-Flt-1 antibody, or an antigen bindingfragment thereof, binds human Flt-1 with an affinity greater than about10⁻⁹ M, greater than about 10⁻¹⁰ M, greater than about 0.5×10⁻¹⁰ M,greater than about 10⁻¹¹ M, greater than about 0.5×10⁻¹¹ M, greater thanabout 10⁻¹² M, or greater than about 0.5×10⁻¹² M. The affinity of anFlt-1 antibody may be measured, for example, in a surface plasmonresonance assay, such as a BIACORE assay.

In some embodiments, an anti-Flt-1 antibody, or an antigen bindingfragment thereof, is characterized by an IC₅₀ below 100 pM, below 10 pM,or below 1 pM in a competition assay with human Flt-1.

In some embodiments, an anti-Flt-1 antibody, or an antigen bindingfragment thereof inhibits the binding and/or activity of VEGF at theFlt-1 receptor. In some embodiments, an anti-Flt-1 antibody, or anantigen binding fragment thereof, is characterized by an IC₅₀ below 100pM, below 10 pM, or below 1 pM for inhibition of binding of VEGF tohuman Flt-1 in a competition assay.

In some embodiments, an anti-Flt-1 antibody, or an antigen bindingfragment thereof inhibits the binding and/or activity of PLGF at theFlt-1 receptor. In some embodiments, an anti-Flt-1 antibody, or anantigen binding fragment thereof, is characterized by an IC₅₀ below 100pM, below 10 pM, or below 1 pM for inhibition of binding of PLGF tohuman Flt-1 in a competition assay.

In some embodiments, an anti-Flt-1 antibody, or an antigen bindingfragment thereof selectively binds Flt-1 and has minimal or noappreciable binding to other VEGF receptors. In some embodiments, ananti-Flt-1 antibody, or an antigen binding fragment thereof selectivelybinds Flt-1 and has minimal or no appreciable binding to VEGFR2 (Flk-1)and/or VEGFR3 (Flt-4).

In some embodiments, an anti-Flt-1 antibody, or an antigen bindingfragment thereof selectively binds human Flt-1, and has minimal or noappreciable binding to other mammalian Flt-1 receptors (e.g., with abinding affinity less than 10⁻⁷M or 10⁻⁶M). In some embodiments, ananti-Flt-1 antibody, or an antigen binding fragment thereof selectivelybinds human Flt-1 and does not bind to monkey Flt-1. In someembodiments, an anti-Flt-1 antibody, or an antigen binding fragmentthereof selectively binds human Flt-1 and does not bind to mouse Flt-1.

In some embodiments, an anti-Flt-1 antibody, or an antigen bindingfragment thereof binds human Flt-1 as well as monkey Flt-1. In someembodiments an anti-Flt-1 antibody, or an antigen binding fragmentthereof binds human Flt-1 as well as mouse Flt-1.

In some embodiments, an anti-Flt-1 antibody, or an antigen bindingfragment thereof, is selected from the group consisting of IgG, F(ab′)₂,F(ab)₂, Fab′, Fab, ScFvs, diabodies, triabodies and tetrabodies.

In some embodiments an anti-Flt-1 antibody, or an antigen bindingfragment thereof, is IgG. In some embodiments an anti-Flt-1 antibody, oran antigen binding fragment thereof, is IgG1.

In some embodiments, a suitable anti-Flt-1 antibody contains an Fcdomain or a portion thereof that binds to the FcRn receptor. As anon-limiting example, a suitable Fc domain may be derived from animmunoglobulin subclass such as IgG. In some embodiments, a suitable Fcdomain is derived from IgG1, IgG2, IgG3, or IgG4. Particularly suitableFc domains include those derived from human or humanized antibodies.

It is contemplated that improved binding between Fc domain and the FcRnreceptor results in prolonged serum half-life. Thus, in someembodiments, a suitable Fc domain comprises one or more amino acidmutations that lead to improved binding to FcRn. Various mutationswithin the Fc domain that effect improved binding to FcRn are known inthe art and can be adapted to practice the present invention. In someembodiments, a suitable Fc domain comprises one or more mutations at oneor more positions corresponding to Thr 250, Met 252, Ser 254, Thr 256,Thr 307, Glu 380, Met 428, His 433, and/or Asn 434 of human IgG1.

In some embodiments, an anti-FLT-1 antibody or antigen binding fragmentcontains a spacer and/or is linked to another entity. In someembodiments, the linker or spacer comprises a sequence at least 50%(e.g., at least 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%,98%, 99%, or 100%) identical to GAPGGGGGAAAAAGGGGGGAP (SEQ ID NO: 1)(GAG linker). In some embodiments, the linker or spacer comprises asequence at least 50% (e.g., at least 55%, 60%, 65%, 70%, 75%, 80%, 85%,90%, 95%, 96%, 97%, 98%, 99%, or 100%) identical toGAPGGGGGAAAAAGGGGGGAPGGGGGAAAAAGGGGGGAP (SEQ ID NO: 2) (GAG2 linker). Insome embodiments, the linker or spacer comprises a sequence at least 50%(e.g., at least 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%,98%, 99%, or 100%) identical to

(SEQ ID NO: 3) GAPGGGGGAAAAAGGGGGGAPGGGGGAAAAAGGGGGGAPGGGGGAAAAAGGGGGGAP (GAG3 linker).

Production of Anti-Flt-1 Antibodies and Antigen Binding Fragments

A recombinant anti-Flt-1 antibody or antigen binding fragment suitablefor the present invention may be produced by any available means. Forexample, a recombinant anti-Flt-1 antibody or antigen binding fragmentmay be recombinantly produced by utilizing a host cell system engineeredto express a recombinant anti-Flt-1 antibody or antigen bindingfragment-encoding nucleic acid.

Where antibodies are recombinantly produced, any expression system canbe used. To give but a few examples, known expression systems include,for example, egg, baculovirus, plant, yeast, or mammalian cells.

In some embodiments, recombinant anti-Flt-1 antibody or antigen bindingfragments suitable for the present invention are produced in mammaliancells. Non-limiting examples of mammalian cells that may be used inaccordance with the present invention include BALB/c mouse myeloma line(NSO/1, ECACC No: 85110503); human retinoblasts (PER.C6, CruCell,Leiden, The Netherlands); and monkey kidney CV1 line transformed by SV40(COS-7, ATCC CRL 1651).

In some embodiments, the present invention provides recombinantanti-Flt-1 antibody or antigen binding fragment produced from humancells. In some embodiments, the present invention provides anti-Flt-1antibody or antigen binding fragment produced from CHO cells.

Pharmaceutical Composition and Administration

The present invention further provides a pharmaceutical compositioncontaining an anti-Flt-1 antibody or antigen binding fragment describedherein and a physiologically acceptable carrier or excipient.

Suitable pharmaceutically acceptable carriers include but are notlimited to water, salt solutions (e.g., NaCl), saline, buffered saline,alcohols, glycerol, ethanol, gum arabic, vegetable oils, benzylalcohols, polyethylene glycols, gelatin, carbohydrates such as lactose,amylose or starch, sugars such as mannitol, sucrose, or others,dextrose, magnesium stearate, talc, silicic acid, viscous paraffin,perfume oil, fatty acid esters, hydroxymethylcellulose, polyvinylpyrolidone, etc., as well as combinations thereof. The pharmaceuticalpreparations can, if desired, be mixed with auxiliary agents (e.g.,lubricants, preservatives, stabilizers, wetting agents, emulsifiers,salts for influencing osmotic pressure, buffers, coloring, flavoringand/or aromatic substances and the like) which do not deleteriouslyreact with the active compounds or interfere with their activity. In apreferred embodiment, a water-soluble carrier suitable for intravenousadministration is used.

A suitable pharmaceutical composition or medicament, if desired, canalso contain minor amounts of wetting or emulsifying agents, or pHbuffering agents. A composition can be a liquid solution, suspension,emulsion, tablet, pill, capsule, sustained release formulation, orpowder. A composition can also be formulated as a suppository, withtraditional binders and carriers such as triglycerides. Oralformulations can include standard carriers such as pharmaceutical gradesof mannitol, lactose, starch, magnesium stearate, polyvinyl pyrrolidone,sodium saccharine, cellulose, magnesium carbonate, etc.

A pharmaceutical composition or medicament can be formulated inaccordance with the routine procedures as a pharmaceutical compositionadapted for administration to human beings. For example, in someembodiments, a composition for intravenous administration typically is asolution in sterile isotonic aqueous buffer. Where necessary, thecomposition may also include a solubilizing agent and a local anestheticto ease pain at the site of the injection. Generally, the ingredientsare supplied either separately or mixed together in unit dosage form,for example, as a dry lyophilized powder or water free concentrate in ahermetically sealed container such as an ampule or sachette indicatingthe quantity of active agent. Where the composition is to beadministered by infusion, it can be dispensed with an infusion bottlecontaining sterile pharmaceutical grade water, saline or dextrose/water.Where the composition is administered by injection, an ampule of sterilewater for injection or saline can be provided so that the ingredientsmay be mixed prior to administration.

Routes of Administration

An anti-Flt-1 antibody or antigen binding fragment described herein (ora composition or medicament containing an anti-Flt-1 antibody or antigenbinding fragment described herein) is administered by any appropriateroute. In some embodiments, an anti-Flt-1 antibody or antigen bindingfragment protein or a pharmaceutical composition containing the same isadministered parenterally. Parenteral administration may be intravenous,intradermal, intrathecal, inhalation, transdermal (topical),intraocular, intramuscular, subcutaneous, intramuscular, and/ortransmucosal administration. In some embodiments, an anti-Flt-1 antibodyor antigen binding fragment or a pharmaceutical composition containingthe same is administered subcutaneously. As used herein, the term“subcutaneous tissue”, is defined as a layer of loose, irregularconnective tissue immediately beneath the skin. For example, thesubcutaneous administration may be performed by injecting a compositioninto areas including, but not limited to, the thigh region, abdominalregion, gluteal region, or scapular region. In some embodiments, ananti-Flt-1 antibody or antigen binding fragment thereof or apharmaceutical composition containing the same is administeredintravenously. In some embodiments, an anti-Flt-1 antibody or antigenbinding fragment thereof or a pharmaceutical composition containing thesame is administered intra-arterially. In some embodiments, ananti-Flt-1 antibody or antigen binding fragment or a pharmaceuticalcomposition containing the same is administered orally. More than oneroute can be used concurrently, if desired.

In some embodiments, administration results only in a localized effectin an individual, while in other embodiments, administration results ineffects throughout multiple portions of an individual, for example,systemic effects. Typically, administration results in delivery of ananti-Flt-1 antibody or antigen binding fragment to one or more targettissues including but not limited lungs and heart.

Dosage Forms and Dosing Regimen

In some embodiments, a composition is administered in a therapeuticallyeffective amount and/or according to a dosing regimen that is correlatedwith a particular desired outcome (e.g., with treating or reducing riskfor a chronic lung disorder, such as bronchopulmonary dysplasia).

Particular doses or amounts to be administered in accordance with thepresent invention may vary, for example, depending on the nature and/orextent of the desired outcome, on particulars of route and/or timing ofadministration, and/or on one or more characteristics (e.g., weight,age, personal history, genetic characteristic, lifestyle parameter,severity of cardiac defect and/or level of risk of cardiac defect, etc.,or combinations thereof). Such doses or amounts can be determined bythose of ordinary skill. In some embodiments, an appropriate dose oramount is determined in accordance with standard clinical techniques.Alternatively or additionally, in some embodiments, an appropriate doseor amount is determined through use of one or more in vitro or in vivoassays to help identify desirable or optimal dosage ranges or amounts tobe administered.

In various embodiments, an anti-Flt-1 antibody or antigen bindingfragment thereof is administered at a therapeutically effective amount.Generally, a therapeutically effective amount is sufficient to achieve ameaningful benefit to the subject (e.g., treating, modulating, curing,preventing and/or ameliorating the underlying disease or condition). Insome particular embodiments, appropriate doses or amounts to beadministered may be extrapolated from dose-response curves derived fromin vitro or animal model test systems.

In some embodiments, a provided composition is provided as apharmaceutical formulation. In some embodiments, a pharmaceuticalformulation is or comprises a unit dose amount for administration inaccordance with a dosing regimen correlated with achievement of thereduced incidence or risk of a chronic lung disorder, such asbronchopulmonary dysplasia.

In some embodiments, a formulation comprising an anti-Flt-1 antibody orantigen binding fragment described herein administered as a single dose.In some embodiments, a formulation comprising an anti-Flt-1 antibody orantigen binding fragment described herein is administered at regularintervals. Administration at an “interval,” as used herein, indicatesthat the therapeutically effective amount is administered periodically(as distinguished from a one-time dose). The interval can be determinedby standard clinical techniques. In some embodiments, a formulationcomprising an anti-Flt-1 antibody or antigen binding fragment describedherein is administered bimonthly, monthly, twice monthly, triweekly,biweekly, weekly, twice weekly, thrice weekly, daily, twice daily, orevery six hours. The administration interval for a single individualneed not be a fixed interval, but can be varied over time, depending onthe needs of the individual.

As used herein, the term “bimonthly” means administration once per twomonths (i.e., once every two months); the term “monthly” meansadministration once per month; the term “triweekly” means administrationonce per three weeks (i.e., once every three weeks); the term “biweekly”means administration once per two weeks (i.e., once every two weeks);the term “weekly” means administration once per week; and the term“daily” means administration once per day.

In some embodiments, a formulation comprising an anti-Flt-1 antibody orantigen binding fragment described herein is administered at regularintervals indefinitely. In some embodiments, a formulation comprising ananti-Flt-1 antibody or antigen binding fragment described herein isadministered at regular intervals for a defined period.

In some embodiments, a formulation comprising an anti-Flt-1 antibody orantigen binding fragment described herein is administered prenatally. Insome embodiments, a formulation comprising an anti-Flt-1 antibody orantigen binding fragment described herein is administered postnatally.

In some embodiments, a formulation comprising an anti-Flt-1 antibody orantigen binding fragment described herein is administered at a dose ofabout 0.5 mg/kg body weight, about 1.0 mg/kg body weight, about 10 mg/kgbody weight or about 20 mg/kg body weight.

In some embodiments, a formulation comprising an anti-Flt-1 antibody orantigen binding fragment described herein is administered at a doseranging from about 0.5 mg/kg body weight to about 20 mg/kg body weight,for example about 1 mg/kg body weight to about 10 mg/kg body weight.

In some embodiments, a formulation comprising an anti-Flt-1 antibody orantigen binding fragment described herein is administered to an adult ata unit dose of about 35 mg, about 70 mg, about 700 mg or about 1400 mg.In some embodiments, a formulation comprising an anti-Flt-1 antibody orantigen binding fragment described herein is administered at a doseranging from about 35 mg to about 1400 mg, for example about 70 mg toabout 700 mg.

In some embodiments, a formulation comprising an anti-Flt-1 antibody orantigen binding fragment described herein is administered to an infantat a unit dose of about 2 mg, about 4 mg, about 40 mg or about 80 mg. Insome embodiments, a formulation comprising an anti-Flt-1 antibody orantigen binding fragment described herein is administered at a doseranging from about 2 mg to about 80 mg, for example about 4 mg to about40 mg.

In some embodiments, administration of an anti-Flt-1 antibody, or anantigen binding fragment thereof reduces the intensity, severity, orfrequency, or delays the onset of at least one BPD sign or symptom. Insome embodiments administration of an anti-Flt-1 antibody, or an antigenbinding fragment thereof reduces the intensity, severity, or frequency,or delays the onset of at least one BPD sign or symptom selected fromthe group consisting of lung inflammation, lung scarring, impaired lunggrowth, early lung injury, prolonged respiratory insufficiency, lunginfections, exercise intolerance, and adverse neurological outcome.

Combination Therapy

In some embodiments, an anti-Flt-1 antibody or antigen binding fragmentis administered in combination with one or more known therapeutic agents(e.g., corticosteroids) currently used for treatment of a musculardystrophy. In some embodiments, the known therapeutic agent(s) is/areadministered according to its standard or approved dosing regimen and/orschedule. In some embodiments, the known therapeutic agent(s) is/areadministered according to a regimen that is altered as compared with itsstandard or approved dosing regimen and/or schedule. In someembodiments, such an altered regimen differs from the standard orapproved dosing regimen in that one or more unit doses is altered (e.g.,reduced or increased) in amount, and/or in that dosing is altered infrequency (e.g., in that one or more intervals between unit doses isexpanded, resulting in lower frequency, or is reduced, resulting inhigher frequency).

EXAMPLES Example 1 Generation and Characterization of High AffinityAnti-Flt-1 Antibodies

Antibody 01A04

An antibody was generated against soluble Flt-1 using traditional mousemonoclonal antibody methodology. Briefly, Balb/c mice were immunizedwith recombinant human soluble Flt-1 (purchased from ABCAM). On day 20post-immunization, animals were titered for anti-sFlt-1 production byELISA (FIG. 1). One mouse was found to be a high titer responder; thisanimal was subsequently boosted with antigen and sacrificed 5 dayslater. Spleen and lymph node cells from this animal were fused to mousemyeloma partners to produce hybridomas. Hybridoma supernatants werescreened versus sFlt-1 antigen, and positive responders were scaled upand re-assayed for binding to both human and mouse sFlt-1, as well asthe ability to compete with sFlt-1 for VEGF binding. There were no crossreactive hybridomas that could bind to both human and mouse sFlt-1.However, among human sFlt-1 reactive hybridomas, several sFlt-1:VEGFantagonists were identified by competition ELISA (see FIG. 2 for arepresentative experiment). The most potent of these, fusion partner01A04, was subjected to three rounds of single cell cloning to achievemonoclonal antibody 01A04. This antibody was further characterized forbinding affinity to sFlt-1 antigen (ELISA, BIACORE and FACs); IC50 insFlt-1:VEGF competition ELISA; and performance in cell based assays.

Antibody 01A04 Characterization—Binding

Following cloning and sub-cloning of the fusion partner parent, multiplesub-clones of the 01A04 parent demonstrated binding to immobilizedsoluble Flt-1 (FIG. 3). One of these subclones, monoclonal01A04-02B10-02G07 was chosen for scale up and cell banking based uponantigen binding, clone morphology and viability. The binding constant of01A04-02B10-02G07 for sFlt-1 antigen was determined via surface plasmonresonance methodology (BIACORE, see FIG. 4). Monoclonal antibody01A04-02B10-02G07 is a sub-nanomolar binder to human sFlt-1.

Antibody 01A04 Characterization—Cross-Reactivity

Binding of monoclonal antibody 01A04 to the Flt-1 receptor expressed oncells was tested with FACS. Three transfected cell lines were testedexpressing human, mouse or cyno Flt-1. Binding to all three cell lineswas tested by incubating the cells with antibody for one hour. Bindingof the antibody to the cells was then revealed with an anti-mouse IgG PEantibody. Results are shown in FIG. 5. Consistent with ELISA and BIACOREdata, monoclonal antibody 01A04 does not bind to mouse Flt-1. However,the antibody does bind to human and cynomolgus Flt-1 expressed on cells.

Antibody 01A04 Characterization—Competition

To estimate the potency of the antibodies, the competition ELISA (usinghuman sFlt-1 and VEGF) that was set-up for the screening of the llamaFabs and IgGs was used. A concentration range from 10 to 0.01 μg/ml ofIgG was tested. Monoclonal antibody 01A04 was assayed versus bothnegative control (purified polyclonal mouse IgG) and positive control(commercial anti-sFlt-1 monoclonal antibody Abcam56300) molecules. Halfmaximal inhibition (IC50) values were calculated. Results are presentedin FIG. 6.

Antibody 01A04 Characterization—Cell Based Assay

Human primary umbilical vein endothelial cells (HUVECs) were stimulatedwith VEGF in the presence or absence of soluble Flt-1 and monoclonalantibody 01A04. VEGF induced activation of cells was assayed bydetermining the phosphorylation status of the VEGF R2 receptor. In thepresence of soluble Flt-1, VEGF induced HUVEC activation is attenuated.Addition of monoclonal antibody 01A04 rescues cell activation byantagonizing soluble Flt-1 (FIG. 7).

Example 2 In Vitro Efficacy of Anti-Flt-1 Antibody

Fetal Pulmonary Artery Endothelial Cell Isolation

Pulmonary artery endothelial cells (PAECs) were harvested from theproximal pulmonary arteries of late gestation control fetal sheep at day135 (day 147 term). Immunohistochemistry with standard endothelialmarkers confirmed the cell phenotype. Low-passage PAECs (p4-5) were thenexposed to ETX, VEGF, sFlt1 or anti-Flt1 alone or in combination.

Growth of PAECs while Exposed to ETX, VEGF, sFlt1 and Anti-Flt1

Fetal PAECs were plated in triplicate at 50,000 cells/well in DMEM with10% FBS into 12 well plates and allowed to adhere overnight in 21%oxygen. The following day (day 0) the cells were washed twice with PBS.DMEM with 2.5% FBS with VEGF, ETX, sFlt1, or anti-F1t1 (alone or incombination) was then added, and cells incubated in 21% oxygen. Finalconcentrations of exogenous factors were as follows: VEGF 50 ng/mL, ETX1 ng/mL, sFlt1 114 ng/mL and anti-Flt1 1800 ng/mL. Experimental mediawas changed daily and cells were counted on day 3 after removing cellswith 0.25% trypsin and counted with a cell counter (Beckman Coulter;Fullerton, Calif.). Growth studies with treatment were performed in DMEMwith 2.5% FBS, based on previous studies that determined that this wasthe lowest serum concentration that supported fetal PAEC survival withsome proliferation.

PAEC Tube Formation Assay

To assay in vitro angiogenesis, we cross-linked rat-tail collagen using0.2% Flavin mononucleotide and a UV Stratalinker 1800 (Stratagene).50,000 cells/well were added in serum free DMEM media supplemented withETX, VEGF, sFlt1 and anti-Flt1 (alone or in combination) and eachcondition was tested in triplicate for each animal. PAECs were thenincubated for 12-18 hours under 3% oxygen conditions based on previousstudies that determined tube formation was more robust in 3% compared to21% oxygen. Branch-point counting was performed in blinded fashion under×10 magnification from each of three wells with three to four field ofview per well. Wells were imaged using an Olympus IX71 fluorescencemicroscope (Olympus).

Statistical Analysis

Statistical analysis was performed with the Prism software package (v.5.0a, GraphPad). Repeated measures one-way analysis of variance (ANOVA)with Bonferroni post-test analysis were performed. P values less than0.05 were considered significant.

Administration of Anti-Flt-1 Antibody to PAECs Exposed to sFLT

Cells were treated with recombinant human VEGF (50 ng/mL), recombinanthuman soluble Flt-1 (sFLT, 114 ng/mL) or antibody for human solubleFlt-1 (a-sFLT, 1800 ng/mL) either alone or in combination. PAEC growthwas measured 3 days after treatment and the number of tube branch pointswas measured 24 hours after treatment.

Results

As shown in FIG. 8, treatment with sFLT and VEGF decreased the number ofPAECs compared to cells treated only with VEGF and treatment, indicatingthat sFLT prevents VEGF from promoting cell growth. When both sFLT anda-sFLT were combined with VEGF, the number of PAECs was brought up tothe levels seen when cells were treated with only VEGF, demonstratingthat a-sFLT inhibits the sFLT-induced decrease in cell growth.

As shown in FIG. 10, treatment with VEGF alone increased the number oftube branch points, as did treatment with VEGF and a-sFLT.Contrastingly, treatment with VEGF and sFLT decreased the number ofbranch points as compared with the cells treated with only VEGF. Whenboth sFLT and a-sFLT were combined with VEGF, the number of branchpoints was comparable to the number seen in the VEGF only group,demonstrating that a-sFLT inhibits the sFLT-induced decrease in thenumber of branch points.

Administration of Anti-Flt-1 Antibody to PAECs Exposed to ETX

Cells were treated with either VEGF (50 ng/mL), endotoxin (ETX, 1ng/mL), VEGF+ETX, EXT+a-sLFT (1800 ng/mL) or EXT+VEGF+a-sFLT. PAECgrowth was measured 3 days after treatment and the number of tube branchpoints was measured 24 hours after treatment.

Results

As shown in FIG. 9, PAEC growth was increased after treatment with VEGFcompared to control (CTL) and PAECs treated with only ETX showeddecreased growth compared to control. The combination of either VEGF ora-sFLT with ETX brought cells numbers up to the level seen in thecontrol group, as did treatment with ETX, VEGF and a-sFLT, demonstratingthat treatment with either VEGF or a-sFLT can reverse the detrimentaleffects of ETX on PAEC growth.

As shown in FIG. 11, the number of branch points increased aftertreatment with VEGF only and cells treated with only ETX showed adecreased number of branch points compared to both the control and VEGFtreated groups. The combination of either VEGF or a-sFLT with ETXbrought the number of branch points up to the level seen in the controlgroup, as did treatment with ETX, VEGF and a-sFLT, demonstrating thattreatment with either VEGF or a-sFLT can reverse the detrimental effectsof ETX on the number of branch points in tubes.

Example 3 In Vivo Efficacy of Anti-Flt-1 Antibody in ETX Model of BPD

Animals

All procedures and protocols were approved by the Animal Care and UseCommittee at the University of Colorado Health Sciences Center. Timedpregnant Sprague-Dawley rats were purchased from Charles RiverLaboratories (Wilmington, Mass.) and maintained in room air at Denver'saltitude (1,600 m; barometric pressure, 630 mmHg; inspired oxygentension, 122 mmHg) for at least 1 week before giving birth. Animals werefed ad libitum and exposed to day-night cycles alternatively every 12hours. Rats were killed with an intraperitoneal injection ofpentobarbital sodium (0.3 mg/g body weight; Fort Dodge Animal Health,Fort Dodge, Iowa).

Animal Model and Study Design

Intra-Amniotic ETX, Vitamin D and Anti-sFLT Administration

An animal model of chorioamnionitis was utilized. At 20 days gestation(term: 22 days), pregnant rats were prepared for receivingintra-amniotic (IA) injections. The timing of injection during the latecanalicular stage of lung development in the rat was selected toparallel the similar stage of human lung development in 24 to 26 weekpremature newborns who are at the highest risk for BPD. Afterpremedication with buprenorphine (0.01-0.05 mg/kg, subcutaneousinjection), laparotomy was performed under general anesthesia with 1-2%isoflurane inhalation via facemask (anesthesia machine: Matrx byMidmark, model VIP3000). During anesthesia and laparotomy, pregnant ratswere kept on a heating pad for preventing hypothermia. Pregnant ratswere randomly assigned to saline control (CTR), endotoxin (ETX), orETX+vitamin D (vit D) group in one study or to saline control (CTR),endotoxin (ETX) or ETX+anti-sFLT in the other study. The CTR groupsreceived 50 μl of normal 136 saline per amniotic sac, the ETX groupsreceived 10 μg of Escherichia coli 055:B55 ETX (Sigma Chemical, St.Louis, Mo.) diluted to 50 μl with normal saline per sac, the ETX+vit Dgroup received 10 μg of Escherichia coli 055:B55 ETX and 50 pg dilutedto 50 μl with normal saline and the ETX+anti-sFLT group received 10 μgof Escherichia coli 055:B55 ETX and low dose (1× molar equivalent) orhigh dose (10× molar equivalent) anti-sFlt1 antibody. Under sterilepreparation, a midline abdominal incision of 3-4 cm in length was madeto expose the amniotic sacs for IA injections. The amniotic sac closestto the right ovary was first identified and injected, and then in acounterclockwise sequence each sac was identified and injected with amaximum of 10 sacs injected per dam. Injections were limited to 10 sacsto prevent maternal mortality due to systemic toxicities fromaccumulating doses of IA ETX. The dose of ETX was established fromprevious studies that demonstrated ETX at lower doses (1-5 μg/sac)failed to induce abnormal lung structure at 14 days of age. The dose ofvit D was established again from previous studies demonstrating vit D athigher doses (500 ng/gm) produced subcutaneous calcium deposits noted inrat pups. The abdominal incision was closed with nylon sutures.Bupivacaine (1-2 mg/kg, intramuscular injection) was applied over theincision wound for postoperative pain control. Pregnant rats weremonitored closely to ensure arousal within 10 minutes after surgery, andrats were placed back to the cages and were monitored for activity andfor signs of bleeding or infection.

Cesarean Section

Two days after IA injections, cesarean section was performed on pregnantrats under general anesthesia with isoflurane inhalation, as describedabove. The fetus in the amniotic sac closest to the right ovary wasfirst delivered, which was followed by delivery of the rest of thefetuses in a counterclockwise sequence, to identify fetuses exposed toIA injections. Cesarean sections were performed instead of allowingvaginal deliveries in order to identify fetuses exposed to specific IAinjections, based on the order of the amniotic sacs and their anatomiclocations related to the ovaries. All of the rat pups in the injectedamniotic sacs were delivered within 5 minutes after onset of anesthesia.Mother rats were then euthanized with pentobarbital sodium. Newborn ratswere immediately dried and placed on a heating pad to avoid hypothermia.Pups received no supplemental oxygen or artificial ventilation at birth.Within 30 minutes after birth, pups were weighed and either sacrificedfor histology or placed with foster mother rats to be raised through 14days. Rat lungs were harvested at birth and 14 days of age forhistological assessment. Survival of the infant rats was monitored andrecorded daily from birth throughout the study period. Survival rate wascalculated as the number of survived pups divided by the number of sacsthat received intra-amniotic injection in each given litter.

Study Measurements

Tissue for Histological Analysis

Animals were killed with intra-peritoneal pentobarbital sodium. Acatheter was placed in the trachea and the lungs were inflated with 4%paraformaldehyde and maintained at 20 cm H₂O pressure for 60 minutes. Aligature was tightened around the trachea to maintain pressure and thetracheal cannula was removed. Lungs were immersed in 4% paraformaldehydeat room temperature overnight for fixation. A 2-mm thick transversesection was taken from the mid-plane of right lower lobe and left lobeof the fixed lungs per animal, respectively. Two sections from eachanimal were processed and embedded in paraffin wax for study.

Bronchoalveolar Lavage (BAL)

Bronchoalveolar lavage was performed on the day of birth (Day 0)according to standard techniques and sFLT levels in the lung weremeasured.

Radial Alveolar Counts (RAC)

Alveolarization was assessed by the RAC method of Emery and Mithal asdescribed (Cooney T P, Thurlbeck W M. The radial alveolar count methodof Emery and Mithal: a reappraisal 1—postnatal lung growth. Thorax 37:572-579, 1982; Cooney T P, Thurlbeck W M. The radial alveolar countmethod of Emery and Mithal: a reappraisal 2—intrauterine and earlypostnatal lung growth. Thorax 37: 580-583, 1982). Respiratorybronchioles were identified as bronchioles lined by epithelium in onepart of the wall. From the center of the respiratory bronchiole, aperpendicular line was dropped to the edge of the acinus connectivetissues or septum or pleura, and the number of septae intersected bythis line was counted.

Statistical Analysis

Statistical analysis was performed with the Prism software package (v.5.0a, GraphPad). Repeated measures one-way analysis of variance (ANOVA)with Bonferroni post-test analysis were performed. P values less than0.05 were considered significant.

Results

As shown in FIG. 12, sFLT levels were significantly (* p<0.05) increasedin rats exposed to ETX in utero compared to the control group andtreatment with Vitamin D decreased the levels of sFLT to the level seenin the control group. This demonstrates that treatment with Vitamin Dcould be used as a therapeutic for treating BPD via the action ofVitamin D on levels of sFLT in the lungs.

As shown in FIG. 13, by morphometric analysis, RAC was decreased in ratsexposed to ETX in utero compared to the control group and in uterodosing with anti-sFLT in rats exposed to ETX significantly (* p<0.05)increased RAC compared to the group only exposed to ETX. Thisdemonstrates that treatment with anti-sFLT could be used as atherapeutic for treating BPD.

Example 4 In Vivo Efficacy of Anti-Flt-1 Antibody in sFLT Model of BPD

Animals

All procedures and protocols were approved by the Animal Care and UseCommittee at the University of Colorado Health Sciences Center. PregnantSprague-Dawley rats were purchased from Charles River Laboratories(Wilmington, Mass.) and maintained in room air at Denver's altitude(1,600 meters; barometric pressure, 630 mmHg; inspired oxygen tension,122 mmHg) for at least 1 week before giving birth. Animals were fed adlibitum and exposed to day-night cycles alternatively every 12 hours.Rats were killed with an intraperitoneal injection of pentobarbitalsodium (0.3 mg/g body wt; Fort Dodge Animal Health, Fort Dodge, Iowa).

Study Design

Intra-Amniotic sFlt-1 Administration

At 20 days gestation (term: 22 days), pregnant rats were prepared forreceiving intra-amniotic injections. The timing of injection during thelate canalicular stage of lung development in the rat was selected toparallel a similar stage of human lung development in 24- to 26-weekpremature newborns who are at the highest risk for BPD. Afterpremedication with buprenorphine (0.01-0.05 mg/kg, intramuscularinjection), laparotomy was performed on pregnant rats under generalanesthesia with 1-2% isoflurane inhalation via a face mask (Anesthesiamachine: Matrx by Midmark, model VIP3000). During anesthesia andlaparotomy, pregnant rats were kept on a heating pad for preventinghypothermia. Pregnant rats were randomly assigned to saline control orsFlt-1 group; the saline group received 50 μL of normal saline peramniotic sac, and the sFlt-1 groups received 50 μg of recombinant humansFlt-1-Fc (R&D Systems, Minneapolis, Minn.) diluted to 50 μL with normalsaline per sac. One sFLT group received a low dose (1× molar equivalent)of anti-sFLT and the other received a high dose (10× molar equivalent)of anti-sFLT. Under sterile preparation, a midline abdominal incision of3-4 cm in length was made to expose the amniotic sacs for intra-amnioticinjections. The amniotic sac closest to the right ovary was firstidentified and injected, and then in a counterclockwise sequence eachsac was identified and injected with a maximum of 10 sacs injected perdam. Limiting sFlt-1 injections to 10 sacs per pregnant rat was toachieve a consistent total dose of sFlt-1 on the individual mother rats,given intra-amniotic sFlt-1 is absorbed into the maternal circulationthrough an intramembranous pathway, which is characterized by amicroscopic network of fetal vasculature on the fetal surface of theplacenta to mediate the transfer of intraamniotic substances into fetaland maternal circulations. Similarly, considering the communicationbetween the amniotic cavity and maternal and fetal circulations throughthe intramembranous pathway, intra-amniotic saline was given in separatelitters to serve as controls. The total number of amniotic sacs in eachmother rat was examined and recorded during laparotomy. The abdominalincision was closed with nylon sutures. Bupivacaine (1-2 mg/kg,subcutaneous injection) was applied over the incision wound forpostoperative pain control. Pregnant rats were monitored closely toensure arousal within 10 minutes after surgery, and rats were placedback to the cages and were monitored for activity, ability to drink andeat, and for signs of bleeding or infection.

Cesarean Section

Two days after intra-amniotic injections, cesarean section was performedon pregnant rats under general anesthesia with isoflurane inhalation, asdescribed above. The fetus in the amniotic sac closest to the rightovary was first delivered, which was followed by delivery of the rest ofthe fetuses in a counterclockwise sequence, to identify fetuses exposedto intra-amniotic injections. The total number of amniotic sacs in eachmother rat was further verified at the time of delivery. The main reasonfor performing cesarean section instead of allowing vaginal delivery isto identify the fetuses exposed to intra-amniotic injections, based onthe order of the amniotic sacs and their anatomic locations related tothe ovaries. All of the rat pups in the injected amniotic sacs weredelivered within 5 minutes after the onset of anesthesia. Maternal ratswere then killed with pentobarbital sodium. Newborn rats wereimmediately placed on a heating pad to avoid hypothermia and were driedmanually with gauze sponges. Pups received no supplemental oxygen orartificial ventilation at birth. The survival rate at birth wasrecorded. Within 30 minutes after birth, the pups were weighed andplaced with foster mother rats in regular cages. For the first 24 h oflife, the newborn pups were monitored closely for mortality or signs ofrespiratory distress.

Rat lungs were harvested at birth for Western blot analysis and at birthand 14 days of age for histological assessment. Hearts were dissectedand weighed at birth and 7 and 14 days of age. Three to nine rats werestudied in each group for each measurement at each time point. Survivalof the infant rats was monitored and recorded daily from birththroughout the study period. Survival rate was calculated as the numberof survived pups divided by the number of sacs that receivedintra-amniotic injection in each given litter. Body weight was measuredat birth and at the time of being killed for study measurements.

Study Measurements

Tissue for Histological Analysis

Animals were killed with intraperitoneal pentobarbital sodium. Acatheter was placed in the trachea, and the lungs were inflated with 4%paraformaldehyde and maintained at 20 cm H₂O pressure for 60 min. Aligature was tightened around the trachea to maintain pressure, and thenthe tracheal cannula was removed. Lungs were then immersed in 4%paraformaldehyde at room temperature for 24 hours for fixation. A2-mm-thick transverse section was taken from the midplane of the rightlower lobe and left lobe of the fixed lungs per animal, respectively, toprocess and embed in paraffin wax.

Immunohistochemistry

Slides with 5 μm paraffin sections were stained with hematoxylin andeosin for assessing alveolar structures and with von Willebrand Factor(vWF), an endothelial cell-specific marker, for quantifying vesseldensity.

Pulmonary Vessel Density

Pulmonary vessel density was determined by counting vWF-stained vesselswith an external diameter at 50 μm or less per high-power field. Thefields containing large airways or vessels with external diameter >50 μmwere avoided.

Radial Alveolar Counts (RAC)

Alveolarization was assessed by the RAC method of Emery and Mithal asdescribed (Cooney T P, Thurlbeck W M. The radial alveolar count methodof Emery and Mithal: a reappraisal 1—postnatal lung growth. Thorax 37:572-579, 1982; Cooney T P, Thurlbeck W M. The radial alveolar countmethod of Emery and Mithal: a reappraisal 2—intrauterine and earlypostnatal lung growth. Thorax 37: 580-583, 1982). Respiratorybronchioles were identified as bronchioles lined by epithelium in onepart of the wall. From the center of the respiratory bronchiole, aperpendicular line was dropped to the edge of the acinus connectivetissues or septum or pleura, and the number of septae intersected bythis line was counted.

Indices of Right Ventricular Hypertrophy

The right ventricle (RV) and left ventricle plus septum (LV+S) weredissected and weighed. The ratios of RV to LV+S weights (RV/LV+S %) andRV/body weights (RV/BW %) were determined to evaluate right ventricularhypertrophy (RVH).

Statistical Analysis

Statistical analysis was performed with the InStat 3.0 software package(GraphPad Software, San Diego, Calif.). Statistical comparisons weremade between groups using t-test or ANOVA with Newman-Keuls post hocanalysis for significance. P<0.05 was considered significant.

Results

As shown in FIGS. 14 and 15, pulmonary vessel density was increased inanimals treated with sFLT+anti-sFLT compared to those treated only withsFLT.

Alveolarization was assessed by the radial alveolar count (RAC) method.As shown in FIG. 16, when analyzed by morphometric analysis, sFLT ratshad significantly (P<0.001) decreased RAC compared with the controlgroup (CTL). Treatment with the low dose of a-sFLT significantly(P<0.01) increased RAC compared to the sFLT group. This indicates thattreatment with a-sFLT can reverse the decrease in alveolarization causedby sFLT.

Right ventricular hypertrophy was assessed by weighing the rightventricle (RV) and left ventricle plus septum (LV+S) and calculating theratio. As shown in FIG. 17, animals exposed to sFLT had a significantlyincreased (P<0.05) RV/(LV+S) ratio compared to the control group.Treatment with the low dose of a-sFLT significantly (P<0.05) decreasedthe RV/(LV+S) ratio compared to the sFLT group. This indicates thattreatment with a-sFLT can reverse the right ventricular hypertrophycaused by sFLT.

The ratio of the right ventricle (RV) to body weight was determined toevaluation right ventricular hypertrophy. As shown in FIG. 18, animalsexposed to sFLT had a significantly (P<0.05) increased RV/body weightratio compared to the control group. Treatment with the low dose ofa-sFLT significantly decreased the RV/body weight ratio (P<0.05)compared to the sFLT group. This indicates that treatment with a-sFLTcan reverse the right ventricular hypertrophy caused by sFLT.

Example 5 In Vivo Efficacy of Anti-Flt-1 Antibody in an Endotoxin (ETX)Model of BPD

Study Design

Intra-Amniotic sFlt-1 and ETX Administration

At 20 days gestation (term: 22 days), pregnant rats were prepared forreceiving intra-amniotic injections. Pregnant rats were randomlyassigned to saline control or ETX (endotoxin) group; the saline groupreceived normal saline injection into the amniotic sac, and the and theETX groups received 10 μg endotoxin per sac. Following intra-amnioticadministration, the abdominal incision was closed and rats weremonitored closely to ensure arousal after surgery.

Cesarean Section and Treatment

Two days after intra-amniotic injections, cesarean section was performedon pregnant rats under general anesthesia, as described above. Pups weretreated twice a week for two weeks with 1 mg/kg anti-sFLT monoclonal, 10mg/kg anti-sFLT monoclonal or 10 mg/kg IgG control (mouse IgG1 isotypecontrol).

Study Measurements

At day 14, rat lungs were harvested for morphometric analysis and forhistological assessment. Body weight of the animals was measured atbirth and at the time of sacrifice. Lungs were fixed after inflationwith 4% paraformaldehyde at 20 cm H₂O. Distal airspace structure wasassessed by Radial Alveolar Counts (RAC). Hearts were collected todetermine right ventricular hypertrophy (RV/LS+S weights)

Body Weight

The body weight of animals was measured to determine if postnatalanti-Flt-1 monoclonal antibody treatment improved body weight followingantenatal ETX treatment. Animals administered ETX in utero followed bypostnatal treatment with IgG (control) or anti-Flt-1 mAb (1 mg/kg or 10mg/kg) were weighed. Animals receiving only ETX or ETX+IgG weighedsignificantly less than control animals (FIG. 19). The weight of animalsreceiving ETX+either dose of anti-Flt-1 mAb was not significantlydifferent from the weight of control animals. These data indicate thatanimals given postnatal anti-Flt-1 mAb have a growth advantage in anendotoxin induced model of BPD.

Radial Alveolar Counts (RAC)

Radial alveolar count was measured to determine if postnatal anti-Flt-1monoclonal antibody treatment improved alveolar growth after antenatalETX treatment. The lungs of animals administered ETX in utero followedby postnatal treatment with IgG (control treatment) or anti-Flt-1monoclonal antibody (1 mg/kg or 10 mg/kg) were studied. Animalsreceiving only ETX or ETX+IgG demonstrated significantly reducedalveolar growth as compared to control animals (FIG. 20). Alveolargrowth in animals receiving ETX+10 mg/kg of anti-Flt-1 monoclonalantibody was significantly better than alveolar growth in animalsreceiving ETX alone. These data indicate that animals given postnatalanti-Flt-1 monoclonal antibody have improved lung structure in anendotoxin induced model of BPD.

Indices of Right Ventricular Hypertrophy

The right ventricle was measured to determine if postnatal anti-Flt-1monoclonal antibody treatment prevented right ventricular hypertrophy(RVH) after antenatal ETX treatment. The hearts of animals administeredETX in utero followed by postnatal treatment with IgG (controltreatment) or anti-Flt-1 monoclonal antibody (1 mg/kg or 10 mg/kg) werestudied. Animals receiving only ETX or ETX+IgG demonstrated asignificantly increased right ventricle ratio as compared to controlanimals (FIG. 21). Right ventricle ratio in animals receiving ETX+eitherdose of anti-Flt-1 monoclonal antibody was not significantly differentfrom the right ventricle ratio of control animals. Right ventricle ratioin animals receiving ETX+either dose of anti-Flt-1 monoclonal antibodywas significantly different from the right ventricle ratio of animalsreceiving ETX alone. These data indicate that animals given postnatalanti-Flt-1 monoclonal antibody have diminished pulmonary hypertension inan endotoxin induced model of BPD.

Lung Structure

Lung structure and pulmonary vessel density was assessed to determine ifpostnatal anti-Flt-1 monoclonal antibody treatment restored lungstructure after antenatal ETX treatment. Lungs of animals administeredETX in utero followed by postnatal treatment with IgG (controltreatment) or anti-Flt-1 monoclonal antibody (1 mg/kg or 10 mg/kg) werestudied (FIG. 22). These data indicate that postnatal anti-sFlt-1monoclonal antibody restores lung structure in experimentalchorioamnionitis.

EQUIVALENTS AND SCOPE

Those skilled in the art will recognize, or be able to ascertain usingno more than routine experimentation, many equivalents to the specificembodiments of the invention described herein. The scope of the presentinvention is not intended to be limited to the above Description, butrather is as set forth in the following claims.

1.-32. (canceled)
 33. A method of treating bronchopulmonary dysplasia(BPD) in an infant comprising administering to an infant in need oftreatment an effective amount of an anti-Flt-1 antibody or antigenbinding fragment thereof, wherein the administration of the anti-Flt-1antibody or antigen binding fragment thereof results in improved lungdevelopment relative to a control.
 34. The method of claim 33, whereinthe anti-Flt-1 antibody or antigen binding fragment thereof has bindingaffinity to human Flt-1 greater than 10⁻¹² M in a surface plasmonresonance binding assay.
 35. The method of claim 33, wherein theanti-Flt-1 antibody or antigen binding fragment thereof is characterizedwith an IC₅₀ below 1 pM in a competition assay with human Flt-I.
 36. Themethod of claim 33, wherein the anti-Flt-1 antibody or antigen bindingfragment thereof does not bind to VEGFR2 and/or VEGFR3.
 37. The methodof claim 33, wherein the anti-Flt-1 antibody or antigen binding fragmentthereof is selected from the group consisting of IgG, F(ab′)₂, F(ab)₂,Fab′, Fab, ScFvs, diabodies, triabodies and tetrabodies.
 38. The methodof claim 37, wherein the anti-Flt-1 antibody or antigen binding fragmentthereof is IgG.
 39. The method of claim 38, wherein the anti-Flt-1antibody or antigen binding fragment thereof is IgG1.
 40. The method ofclaim 38 or 39, wherein the anti-Flt-1 antibody or antigen bindingfragment thereof is a monoclonal antibody, wherein the monoclonalantibody contains a human Fc region.
 41. The method of claim 40, whereinthe Fc region contains one or more mutations that enhance the bindingaffinity between the Fc region and the FcRn receptor such that the invivo half-life of the antibody is prolonged.
 42. The method of claim 41,wherein the Fc region contains one or more mutations at one or morepositions corresponding to Thr 250, Met 252, Ser 254, Thr 256, Thr 307,Glu 380, Met 428, His 433, and/or Asn 434 of human IgG1.
 43. The methodof claim 33, wherein the anti-Flt-1 antibody or antigen binding fragmentthereof is administered parenterally.
 44. The method of claim 43,wherein the parenteral administration is selected from intravenous,intradermal, intrathecal, inhalation, transdermal (topical),intraocular, intramuscular, subcutaneous, pulmonary delivery, and/ortransmucosal administration.
 45. The method of claim 33, wherein theeffective amount of anti-Flt-1 antibody or antigen-binding fragmentthereof ranges from 0.5 mg/kg body weight to about 20 mg/kg body weightper dose.
 46. The method of claim 33, wherein the anti-Flt-1 antibody orantigen binding fragment thereof is administered bimonthly, monthly,triweekly, biweekly, weekly, daily, or at variable intervals.
 47. Themethod of claim 33, wherein the anti-Flt-1 antibody or antigen bindingfragment thereof is delivered to one or more target tissues selectedfrom lungs and heart.
 48. The method of claim 33, wherein theadministration of the anti-Flt-1 antibody or antigen binding fragmentthereof results in growth of healthy lung tissue, decreased lunginflammation, increased alveologenesis, increased angiogenesis, improvedstructure of pulmonary vascular bed, reduced lung scarring, improvedlung growth, reduced respiratory insufficiency, improved exercisetolerance, reduced adverse neurological outcome, and/or improvedpulmonary function relative to a control.
 49. The method of claim 33,further comprising co-administering at least one additional agent ortherapy selected from a surfactant, oxygen therapy, ventilator therapy,a steroid, vitamin A, inhaled nitric oxide, high calorie nutritionalformulation, a diuretic, and/or a bronchodilator.
 50. The method ofclaim 33, wherein the infant is an unborn infant and the anti-Flt-1antibody or antigen binding fragment thereof is administered to theinfant via intra-amniotic injection.
 51. The method of claim 33, whereinthe method comprises parental administration to the infant after birth.